Interruption of Mesalamine and Reduction of the Blood Concentration of the Active Metabolites of Azathioprine: Possible Causes of Ulcerative Colitis Relapse

[1]  C. Mulder,et al.  Dose-Dependent Influence of 5-Aminosalicylates on Thiopurine Metabolism , 2007, The American Journal of Gastroenterology.

[2]  A. Andriulli,et al.  Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy , 2007, Alimentary pharmacology & therapeutics.

[3]  M. Schwab,et al.  Adherence to thiopurine treatment in out‐patients with Crohn’s disease , 2007, Alimentary pharmacology & therapeutics.

[4]  B. Xia,et al.  N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[5]  H. Herfarth,et al.  Monitoring of Thiopurine Methyltransferase Activity in Postsurgical Patients With Crohn's Disease During 1 Year of Treatment With Azathioprine or Mesalazine , 2007, Therapeutic drug monitoring.

[6]  M. Montico,et al.  Glutathione‐S‐transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[7]  U. Klotz,et al.  Thiopurine Treatment in Inflammatory Bowel Disease , 2007, Clinical pharmacokinetics.

[8]  R. Gearry,et al.  Thiopurine Treatment in Inflammatory Bowel Disease , 2007, Clinical pharmacokinetics.

[9]  A. Timmer,et al.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. , 2007, The Cochrane database of systematic reviews.

[10]  A. Bousvaros,et al.  5‐Aminosalicylate therapy is associated with higher 6‐thioguanine levels in adults and children with inflammatory bowel disease in remission on 6‐mercaptopurine or azathioprine , 2006, Inflammatory bowel diseases.

[11]  P. Lionetti,et al.  TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  U. Klotz,et al.  Effects of aminosalicylates on thiopurine S‐methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease , 2005, Alimentary pharmacology & therapeutics.

[13]  C. Lewis,et al.  Mutation in the ITPA Gene Predicts Intolerance to Azathioprine , 2003, Nucleosides, nucleotides & nucleic acids.

[14]  Richard M Weinshilboum,et al.  N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis , 2002, American Journal of Gastroenterology.

[15]  S. Cucchiara,et al.  Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey , 2002, Alimentary pharmacology & therapeutics.

[16]  R. Weinshilboum,et al.  Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide , 2001, Gut.

[17]  D. Present.  Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents. , 2000, Gastroenterology.

[18]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[19]  R. Boulieu,et al.  Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. , 1998, Clinical chemistry.

[20]  R. Weinshilboum,et al.  Olsalazine and 6‐mercaptopurine‐related bone marrow suppression: A possible drug‐drug interaction , 1997, Clinical pharmacology and therapeutics.